From January 7, 2024 to March 29, 2024, the company has repurchased 8,638,000 shares, representing 2.85% for $190.71 million. With this, the company has completed the repurchase of 8,638,000 shares, representing 2.85% for $190.71 million under the buyback announced on January 8, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.57 USD | +0.78% | -3.11% | -14.26% |
May. 20 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
May. 14 | Transcript : Exelixis, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 02:35 PM |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.26% | 5.95B | |
+12.30% | 116B | |
+12.15% | 106B | |
-8.14% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.33% | 16.33B | |
+5.80% | 14.14B | |
+28.03% | 12.02B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on January 8, 2024.